Karyotype abnormalities and their clinical signifi cance in a group of chronic myeloid leukemia patients treated with hematopoietic stem cell transplantation

Authors

  • Luize Otero Instituto Nacional do Câncer
  • Maria Helena Ornellas Instituto Nacional do Câncer
  • Rita de Cássia Tavares Instituto Nacional do Câncer
  • Virgínia Pires Instituto Nacional do Câncer
  • Eliana Abdelhay Instituto Nacional do Câncer
  • Luiz Fernando Bouzas Instituto Nacional do Câncer
  • Teresa de Souza Fernandez Instituto Nacional do Câncer

Keywords:

Hematopoietic stem cell transplantation, Chronic myeloid leukemia, Chromosome aberrations, Philadelphia chromosome, Prognosis

Abstract

CONTEXT AND OBJECTIVE: Following hematopoietic stem cell transplantation (HSCT), karyotyping is a valuable tool for monitoring engraftment and disease status. Few studies have examined the prognostic signifi cance of karyotypes in patients who underwent HSCT for chronic myeloid leukemia (CML). The objective of this study was to evaluate the signifi cance of pretransplantation cytogenetic status in relation to outcomes following HSCT in CML patients. DESIGN AND SETTING: Case series study at Instituto Nacional do Câncer (INCA), Rio de Janeiro, Brazil. METHODS: Cytogenetic analysis was performed by G banding on 39 patients treated with HSCT. RESULTS: Thirty-one patients were in the chronic phase and eight were in the accelerated phase. Prior to HSCT, additional chromosomal abnormalities on the Philadelphia (Ph) chromosome were found in 11 patients. The most frequent additional abnormality was a double Ph, which was observed in four cases. Following HSCT, full chimeras were observed in 31 patients (79.5%). Among these, 23 (82.3%) had presented Ph as the sole abnormality. Mixed chimeras were observed in seven patients, of which three had additional abnormalities. Only one case did not present any cytogenetic response. Five patients presented cytogenetic relapse associated with clinical relapse following HSCT. Twenty-seven patients are still alive and present complete hematological and cytogenetic remission. CONCLUSION: In our study, the presence of additional abnormalities was not associated with worse outcome and relapse risk. Also, no differences in survival rates were observed. Our study supports the view that classical cytogenetic analysis remains an important tool regarding HSCT outcome.

Downloads

Download data is not yet available.

Author Biographies

Luize Otero, Instituto Nacional do Câncer

Biologist, Bone Marrow Transplantation Center, Instituto Nacional do Câncer (INCA). Postgraduate student of School of Medical Sciences, Universidade do Estado do Rio de Janeiro (UERJ), Rio de Janeiro, Rio de Janeiro, Brazil.

Maria Helena Ornellas, Instituto Nacional do Câncer

MD, PhD. Hematologist and Researcher, Bone Marrow Transplantation Center, Instituto Nacional do Câncer (INCA). Professor, Department of Pathology, School of Medical Sciences, Universidade do Estado do Rio de Janeiro (UERJ), Rio de Janeiro, Rio de Janeiro, Brazil.

Rita de Cássia Tavares, Instituto Nacional do Câncer

MD. Hematologist, Bone Marrow Transplantation Center, Instituto Nacional do Câncer (INCA), Rio de Janeiro, Rio de Janeiro, Brazil.

Virgínia Pires, Instituto Nacional do Câncer

PhD. Biologist and Researcher, Bone Marrow Transplantation Center, Instituto Nacional do Câncer (INCA), Rio de Janeiro, Rio de Janeiro, Brazil.

Eliana Abdelhay, Instituto Nacional do Câncer

PhD. Head of Laboratory Unit, Bone Marrow Transplantation Center, Instituto Nacional do Câncer (INCA), Rio de Janeiro, Rio de Janeiro, Brazil.

Luiz Fernando Bouzas, Instituto Nacional do Câncer

MD, MSc. Head of Bone Marrow Transplantation Center, Instituto Nacional do Câncer (INCA), Rio de Janeiro, Rio de Janeiro, Brazil.

Teresa de Souza Fernandez, Instituto Nacional do Câncer

PhD. Biologist and Researcher, Bone Marrow Transplantation Center, Instituto Nacional do Câncer (INCA), Professor, School of Medical Sciences, Universidade do Estado do Rio de Janeiro (UERJ), Rio de Janeiro, Rio de Janeiro, Brazil.

References

Shet AS, Jahagirdar BN, Verfaillie CM. Chronic myelogenous leukemia: mechanisms underlying disease progression. Leuke- mia. 2002;16(8):1402-11.

Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol. 2002;107(2):76-94.

Kantarjian HM, Keating MJ, Talpaz M, et al. Chronic myel- ogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med. 1987;83(3):445-54.

Kantarjian HM, Smith TL, McCredie KB, et al. Chronic myelogenous leukemia: a multivariate analysis of the associations of patient charac- teristics and therapy with survival. Blood. 1985;66(6):1326-35.

Singh S, Wass J, Vincent PC, Young GA, Gunz FW. Significance of secondary cytogenetic changes in patients with Ph-positive chronic granulocytic leukemia in the acute phase. Cancer Genet Cytogenet. 1986;21(3):209-20.

Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031-7.

Clift RA, Anasetti C. Allografting for chronic myeloid leukae- mia. Baillieres Clin Haematol. 1997;10(2):319-36.

Speck B, Bortin MM, Champlin R, et al. Allogeneic bone-mar- row transplantation for chronic myelogenous leukaemia. Lancet. 1984;1(8378):665-8.

Seabright M. A rapid banding technique for human chromo- somes. Lancet. 1971;2(7731):971-2.

Mitelman F. ISCN 1995. An International System for Human Cytogenetic Nomenclature. Basel: Karger; 1995. Available from: http://www.iscn1995.org/. Accessed in 2007 (Jun 4).

Farag SS, Ruppert AS, Mrózek K, et al. Prognostic sig- nificance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon- alpha: a Cancer and Leukemia Group B study. Int J Oncol. 2004;25(1):143-51.

Schoch C, Haferlach T, Kern W, et al. Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate. Leukemia. 2003;17(2):461-3.

Przepiorka D, Thomas ED. Prognostic significance of cytoge- netic abnormalities in patients with chronic myelogenous leukemia. Bone Marrow Transplant. 1988;3(2):113-9.

Slovak ML, Kopecky KJ, Wolman SR, et al. Cytogenetic correlation with disease status and treatment outcome in advanced stage leukemia post bone marrow transplantation: a Southwest Oncology Group study (SWOG-8612). Leuk Res. 1995;19(6):381-8.

Konstantinidou P, Szydlo RM, Chase A, Goldman JM. Cytoge- netic status pre-transplant as a predictor of outcome post bone marrow transplantation for chronic myelogenous leukaemia. Bone Marrow Transplant. 2000;25(2):143-6.

Downloads

Published

2007-07-07

How to Cite

1.
Otero L, Ornellas MH, Tavares R de C, Pires V, Abdelhay E, Bouzas LF, Fernandez T de S. Karyotype abnormalities and their clinical signifi cance in a group of chronic myeloid leukemia patients treated with hematopoietic stem cell transplantation. Sao Paulo Med J [Internet]. 2007 Jul. 7 [cited 2025 Mar. 17];125(4):246-9. Available from: https://periodicosapm.emnuvens.com.br/spmj/article/view/2137

Issue

Section

Short Communication